Evidence map›Paper›PMID 38462606›Full record

ReviewMolecular neurodegeneration2024

Updates on mouse models of Alzheimer's disease.

Michael Z Zhong, Thomas Peng, Mariana Lemos Duarte, Minghui Wang, Dongming Cai

Open access · goldAbstract readReview
In one paragraph

Review in Molecular neurodegeneration, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 118 papers.

0numbers the graph read from it
0cells of the map it votes in
118citing papers in PubMed
47.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

118 citing papers in PubMed, 147 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Increased Amyloidogenic Neuronal Injury in HIV-1-infected APP-KI Alzheimer's disease mice.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

58 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 5 institutions in 1 country.

Michael Z Zhong *Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
Thomas Peng *Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
Mariana Lemos DuarteDepartment of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA. mariana.lemosduarte@mssm.edu.
Minghui WangDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA. minghui.wang@mssm.edu.
Dongming CaiDepartment of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA. cai00268@umn.edu.ORCID 0000-0002-0601-6826
Boston University · USJames J. Peters VA Medical Center · USMount Sinai Hospital · USScarsdale Public Schools · USUniversity of Minnesota · US

Funding

Novel Network Biology Approaches to Reposition FDA-approved Drugs for Alzheimer's DiseaseR01AG068030 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI BRENNAND, KRISTEN JENNIFER, CAI, DONGMING · 2020 to 2024
$4.2M
Dissect the interplay between sex and APOE at the single cell level to uncover novel pathways, targets and therapeutics for Alzheimer's diseaseRF1AG074010 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI CAI, DONGMING, ZHANG, BIN · 2021 to 2021
$3.6M
Characterization of ApoE4 Induced Phospholipid Dysregulation in AD PathogenesisR01AG048923 · NIA · UNIVERSITY OF MINNESOTA · PI CAI, DONGMING · 2015 to 2025
$3.1M
Characterization of ApoE4 Induced Phospholipid Dysregulation in AD PathogenesisRF1AG048923 · NIA · UNIVERSITY OF MINNESOTA · PI CAI, DONGMING · 2021 to 2021
$2.1M
MicroRNA Regulation of Phospholipid Homeostasis in Alzheimer's Disease PathogenesisI01BX003380 · VA · MINNEAPOLIS VA MEDICAL CENTER · PI CAI, DONGMING · 2017 to 2025
–
Novel Disease-modifying Small Molecules for Treatment of Alzheimer's Disease”I01BX005934 · VA · MINNEAPOLIS VA MEDICAL CENTER · PI Dongming Cai · 2023 to 2026
–
BLRD VA I01 BX003380BLRD VA I01 BX005934NIA NIH HHS R01 AG048923NIA NIH HHS R01 AG068030NIA NIH HHS RF1 AG048923NIA NIH HHS RF1AG048923NIA NIH HHS RF1 AG074010NIA NIH HHS RF1AG074010NIA NIH HHS RO1AG068030
6 · The paper itself

Abstract

Alzheimer's disease (AD) is the most common neurodegenerative disease in the United States (US). Animal models, specifically mouse models have been developed to better elucidate disease mechanisms and test therapeutic strategies for AD. A large portion of effort in the field was focused on developing transgenic (Tg) mouse models through over-expression of genetic mutations associated with familial AD (FAD) patients. Newer generations of mouse models through knock-in (KI)/knock-out (KO) or CRISPR gene editing technologies, have been developed for both familial and sporadic AD risk genes with the hope to more accurately model proteinopathies without over-expression of human AD genes in mouse brains. In this review, we summarized the phenotypes of a few commonly used as well as newly developed mouse models in translational research laboratories including the presence or absence of key pathological features of AD such as amyloid and tau pathology, synaptic and neuronal degeneration as well as cognitive and behavior deficits. In addition, advantages and limitations of these AD mouse models have been elaborated along with discussions of any sex-specific features. More importantly, the omics data from available AD mouse models have been analyzed to categorize molecular signatures of each model reminiscent of human AD brain changes, with the hope to guide future selection of most suitable models for specific research questions to be addressed in the AD field.

Indexed as

Alzheimer DiseaseNeurodegenerative DiseasesAmyloid beta-PeptidesAmyloid beta-Protein PrecursorAnimalsDisease Models, AnimalFemaleHumansMaleMiceMice, Transgenictau ProteinsAmyloid beta-PeptidesAmyloid beta-Protein Precursortau Proteins

Identifiers

PMID38462606
PMCPMC10926682
OpenAlexW4392656549

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.